rhophilin associated tail protein 1BGenealiases: []
Q-omics provides the consensus-scored ROPN1B profile across patient tissues and cancer cell-line models. ROPN1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ROPN1B is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ROPN1B RNA expression shows 18,379 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where ROPN1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ROPN1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ROPN1B survival associations across molecular data types. ROPN1B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ROPN1B RNA expression–survival associations across cancer types. High ROPN1B expression shows unfavorable associations in STAD, ACC and COAD, but favorable associations in UVM, HNSC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ROPN1B RNA expression.
This table summarizes ROPN1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ROPN1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ROPN1B shows lower tumor expression in KIRC, THCA, BRCA, KICH and HNSC and higher tumor expression in PRAD. The KIRC box plot shows higher ROPN1B RNA expression in normal versus tumor tissue (log2 FC = −0.158, t-test p < 0.001).
This table shows molecular features associated with ROPN1B in patient tissues and cancer cell lines. In patient samples, ROPN1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ROPN1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
